Correction: Nebivolol, a β 1 -adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis

Georgios Liappas; Guadalupe González-Mateo; Anna Rita Aguirre; Hugo Abensur; Patricia Albar-Vizcaino; Emilio González Parra; Pilar Sandoval; Laura García Ramírez; Gloria del Peso; Juan Manuel Acedo; María A. Bajo; Rafael Selgas; José A. Sánchez Tomero; Manuel López-Cabrera; Abelardo Aguilera

doi:10.18632/oncotarget.16782

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Nebivolol, a β₁-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis

Georgios Liappas _, Guadalupe González-Mateo, Anna Rita Aguirre, Hugo Abensur, Patricia Albar-Vizcaino, Emilio González Parra, Pilar Sandoval, Laura García Ramírez, Gloria del Peso, Juan Manuel Acedo, María A. Bajo, Rafael Selgas, José A. Sánchez Tomero, Manuel López-Cabrera and Abelardo Aguilera

PDF | How to cite

Oncotarget. 2017; 8:24045-24045. https://doi.org/10.18632/oncotarget.16782

Metrics: PDF 2469 views | ?

Present: The currently listed funding information is incorrect.

Corrected: The proper funding information is listed below.

Original article: Oncotarget. 2016; 7(21):30133-30146. DOI:10.18632/oncotarget.8780.

FUNDING

This work was supported by Menarini Spain, grants PI 15/00598 from Fondo de Investigaciones Sanitarias (FIS) Carlos III Institute to A.A .; SAF2013-47611R from The Ministry of Economy and Competitiveness and grant S2010 / BMD-2321 (FIBROTEAM Consortium) from Autonomous Community of Madrid to M.L.-C .; G.L. Was Fully supported from theEuropean ETRiPD Marie Curie Project.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16782

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Nebivolol, a β₁-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Nebivolol, a β1-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis

Correction: Nebivolol, a β₁-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis